Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Teva to Market Parkinson’s Drug in China for Lundbeck

publication date: Feb 26, 2010
H Lundbeck A/S, a pharmaceutical company headquartered in Denmark, expanded its Asian sales agreement with Teva Pharma to include Azilect (rasagiline), a treatment for Parkinson’s disease. The agreement gives Teva the right to market Azilect in China and five other Asian countries. Lundbeck will be responsible for conducting clinical trials of the drug and obtaining SFDA approval. More details...

Stock Symbols: (CPH: LUN) (NSDQ: TEVA)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital